Company intelligence / Profile preview
Argorna Pharmaceuticals
- Ownership
- Private
- Development stage
- Other
01
Overview
Argorna Pharmaceuticals is an innovative RNA drug company founded in 2020 by leading scientists including Nobel Prize winners. The company has developed proprietary platforms for liver-targeted RNAi and LNP-based delivery of mRNA vaccines. Its lead program is a COVID‑19 mRNA vaccine that has completed Phase I/II clinical trials demonstrating safety and immunogenicity in adults. The company also holds patents in the field of RNA therapeutics and maintains large-scale production capabilities for mRNA vaccines.[1][2]
- Therapeutic areas
- PulmonologyCardiovascularRheumatologyImmunologyOtherOncologyInfectious Diseases
- Modalities
- mRNA vaccinesRNAi therapeuticsOligonucleotide APIs[1][2][7]
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Guangzhou Ribobio Co., Ltd. – co-developer on the COVID‑19 vaccine project.[1]
Beyond the preview
Go deeper on Argorna Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Argorna Pharmaceuticals.